Condition: Asthma
Intervention: Biological: Benralizumab
Sponsor: AstraZeneca
Not yet recruiting – verified September 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
Condition: Asthma
Interventions: Drug: Benralizumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified August 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
Condition: Asthma
Interventions: Biological: Benralizumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified June 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Severe Asthma Reduced in Phase 3 Benralizumab Tests – Lung Disease News
Lung Disease News |
Severe Asthma Reduced in Phase 3 Benralizumab Tests
Lung Disease News AstraZeneca recently announced that the new severe asthma medicine benralizumab met the primary endpoints in two Phase 3 registration trials. Findings of the trials called SIROCCO and CALIMA, revealed that the monoclonal antibody compound was well … |
View full post on asthma – Google News
Benralizumab: a unique IL-5 inhibitor for severe asthma – Dove Medical Press
|
Benralizumab: a unique IL-5 inhibitor for severe asthma
Dove Medical Press Abstract: The presence of eosinophilic inflammation is a characteristic feature of chronic and acute inflammation in asthma. An estimated 5%–10% of the 300 million people worldwide who suffer from asthma have a severe form. Patients with eosinophilic … |
View full post on asthma – Google News
Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
Condition: Asthma
Interventions: Biological: Benralizumab; Biological: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified December 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Benralizumab: for asthma, not yet for COPD.
 |
Benralizumab: for asthma, not yet for COPD.
Lancet Respir Med. 2014 Oct 8;
Authors: Fabbri LM
PMID: 25306558 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Benralizumab Improves Asthma Symptoms – Medscape
|
Benralizumab Improves Asthma Symptoms
Medscape SAN DIEGO — Benralizumab reduces exacerbations and improves lung function in asthma patients with elevated eosinophil counts, according to a phase 2 trial. Some patients with severe asthma fail to achieve adequate control, even with high-dose inhaled … |
View full post on asthma – Google News
MedImmune to present Phase IIb asthma data on benralizumab and … – News-Medical.net
|
MedImmune to present Phase IIb asthma data on benralizumab and …
News-Medical.net In the Phase IIb data being presented, both benralizumab and tralokinumab show promising safety and efficacy outcomes, suggesting they may offer important new therapeutic options for patients with specific forms of severe, uncontrolled asthma. |
View full post on asthma – Google News